July 31, 2013
07:28 EDT QCOR Questcor price target raised to $73 from $57 at Oppenheimer
Oppenheimer increased its target on Questcor after the company reported higher than expected Q2 revenue. The firm believes that sales of the company's Acthar treatment continue to be strong. Oppenheimer remains upbeat on Acthar's outlook and keeps an Outperform rating on the stock.